Abiopharma

🔍 Tezel Ahmet (Executive)

Company: LivaNova PLC (LIVN)

Report Date: 2026-08-11

Detailed Transactions and Holdings:

• Acquired 12,692 shares of Ordinary Shares at $52.68 per share (Direct)
  Date: 2026-08-11 | Code: M | equity_swap_involved: 0 | shares_owned_after: 18,782.00 | transaction_form_type: 4
• Sold 8,589 shares of Ordinary Shares at $77.86 per share (Direct)
  Date: 2026-08-11 | Code: D | equity_swap_involved: 0 | shares_owned_after: 10,193.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,428 shares of Ordinary Shares at $77.86 per share (Direct)
  Date: 2026-08-11 | Code: F | equity_swap_involved: 0 | shares_owned_after: 8,765.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 2,675 shares of Ordinary Shares at $77.7355 per share (Direct)
  Date: 2026-08-11 | Code: S | equity_swap_involved: 0 | shares_owned_after: 6,090.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 12,692 shares of Stock Appreciation Rights at $52.68 per share (Derivative)
  Date: 2026-08-11 | Code: M | Expires: 2034-06-15 | equity_swap_involved: 0 | shares_owned_after: 12,691.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: Shares withheld in payment of the base price in connection with the exercise of stock appreciation rights (SARs).
• F2: Shares withheld to satisfy tax liability.
• F3: The shares were sold in multiple open-market transactions at prices from $77.6684 to $77.7900; the reported price reflects the weighted-average sale price. The reporting person undertakes to provide to LivaNova PLC (the Company), any security holder of the Company, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price.
• F4: The SARs were granted on June 15, 2024, vesting in four equal annual installments beginning June 15, 2025, and are subject to forfeiture prior to vesting under the terms of the Amended and Restated LivaNova PLC 2022 Incentive Award Plan and the award agreement.